Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 34028812 · doi:10.1002/14651858.CD004034.pub4
What was done
This Cochrane systematic review searched major databases through July 2020 for randomized controlled trials lasting at least 12 months that evaluated pharmacological treatment of hypertension in individuals without a history of cerebrovascular disease. Primary outcomes included incident dementia and cognitive decline (e.g., Mini-Mental State Examination, MMSE), alongside blood pressure changes, adverse events, and quality of life. Risk of bias and evidence certainty were evaluated using standard Cochrane and GRADE methodologies.
What was found
Twelve studies comprising 30,412 participants (follow-up 1 to 5 years) were included. In 4 placebo-controlled trials, antihypertensive therapy did not significantly reduce incident dementia compared to placebo (236/7,767 vs 259/7,660; OR 0.89, 95% CI 0.72 to 1.09; very low-certainty evidence). In 5 placebo-controlled trials, active treatment was associated with a slight difference in MMSE change (MD 0.20 points, 95% CI 0.10 to 0.29; very low-certainty evidence). Antihypertensive therapy reduced systolic blood pressure by a mean difference of -9.25 mmHg (95% CI -9.73 to -8.78) and diastolic blood pressure by -2.47 mmHg (95% CI -2.70 to -2.24) across placebo-controlled trials (low-certainty evidence). Adverse event dropouts and quality-of-life outcomes varied considerably across trials and could not be meta-analyzed.
Why it matters
Although observational studies suggest treating hypertension protects against dementia, randomized trial evidence in populations without prior cerebrovascular disease remains inconclusive and fails to demonstrate a clinically meaningful benefit on cognition.
Limits
Follow-up durations (1 to 5 years) were likely too short to capture meaningful differences in dementia incidence. Dementia and cognitive decline were secondary endpoints in most included trials. Additional limitations include substantial contamination (placebo arm participants initiating antihypertensive therapy), failure to meet planned recruitment targets, early trial terminations, and indirectness, resulting in very low GRADE certainty for cognitive outcomes.
Cited by
- supports Studies show that administering antihypertensive medications has a positive impact on cognition.